Top
image credit: Adobe Stock

OBiO, Chinagene Sign Gene Therapy Manufacturing Services Agreement

May 8, 2023

OBiO Technology Corp., a provider of gene and cell therapy-focused biotechnology, entered into a strategic commercial manufacturing collaboration with Chinagene, a developer of clinical genetic diagnosis, and gene therapy drugs.

Under the agreement, OBiO will provide contract development and manufacturing services to Chinagene for their gene therapy products, including large-scale cGMP manufacturing service for clinical trials, process characterization and validation services, product formulation and filling services, and commercial manufacturing.

Read More on Contract Pharma